Solaris Energy Infrastructure Announces Dual Listing on NYSE Texas

HOUSTON--(BUSINESS WIRE)-- Solaris Energy Infrastructure, Inc. (NYSE: SEI) (“Solaris”) announced today the dual listing of its Class A common stock on NYSE Texas, Inc. (“NYSE Texas”), the newly launched fully electronic equities exchange headquartered in Dallas, Texas.

Solaris will maintain its primary listing on the New York Stock Exchange (“NYSE”) and continue to trade under the same ticker symbol, “SEI,” on the NYSE and NYSE Texas.

“We are pleased to join the NYSE Texas as a Founding Member. Solaris is proud of its longstanding presence in Texas, where the company was established and continues to be headquartered. Many of our customers, suppliers and employees are also based in Texas or have a significant presence here, and we are excited to further support Texas business development with this dual listing,” said Bill Zartler, Solaris’ Chairman and Chief Executive Officer.

“Solaris is a key provider of energy and power solutions in Texas, and we are honored to welcome them to NYSE Texas as a Founding Member,” said Chris Taylor, Chief Development Officer, NYSE Group.

About Solaris

Solaris Energy Infrastructure, Inc. (NYSE: SEI) provides mobile and scalable equipment-based solutions for use in distributed power generation as well as the management of raw materials used in the completion of oil and natural gas wells. Headquartered in Houston, Texas, Solaris serves multiple U.S. end markets, including energy, data centers, and other commercial and industrial sectors. For more details, visit solaris-energy.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250730998179/en/

Yvonne Fletcher
Senior Vice President, Finance and Investor Relations
(281) 501-3070
[email protected]

Source: Solaris Energy Infrastructure, Inc.

You May Also Be Interested In

• FPT and NAVER Cloud Form Strategic Alliance to Fuel AI Innovation Across Asia-Pacific and Beyond
• Crypto Market News: Coinbase Unveils Global Exchange With $30B in Bitcoin Options as Pepeto Buyers Pile In
• Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer